INCY 70.50 Incyte Corp $INCY Hit a 52 week high of 71.06

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
INCY 70.50 Incyte Corp $INCY Hit a 52 week high of 71.06 Closing the day 09:45 at 70.50 -0.56 -0.79% With a day low of 70.35 and a total volume of 98,038.

INCY Recent Posts: http://investorshangout.com/Incyte-Corporation-INCY-54453/

INCY Incyte Corp Recent Headline News

Watch for Incyte to Potentially Pullback After Gaining 2.37% Yesterday
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.59 (+0.53)

SmarTrend Watching for Potential Pullback in Shares of Incyte After 2.37% Gain
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.59 (+0.53)

Incyte Earnings Review: 11 Days after Announcement Shares Up 8.0% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 1:34PM CST
A week ago on October 30th, 2014 Incyte (NASDAQ:INCY) reported earnings and analysts, on average, expected earnings of $0.09 on sales of $149.9 million. Incyte actually reported earnings of $0.33 per share on sales of $198.1 million, beating EPS estimates by $0.24 and beating revenue estimates by $48.3 million. Shares of Incyte have climbed from $64.18 to $69.32, representing a gain of 8.0% since the company reported earnings 11 days ago.
INCY: 71.59 (+0.53)

Uptrend Call Working As Incyte Stock Rises 35.6% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 10:48AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 3 weeks, Incyte has returned 35.57% as of today's recent price of $69.25.
INCY: 71.59 (+0.53)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.21 (+0.01), PCYC: 138.86 (+4.57), CLDX: 14.63 (+0.17), INCY: 71.59 (+0.53), BIND: 9.85 (+0.04), CELG: 107.56 (-0.29), OMER: 19.05 (unch), VSTM: 9.23 (+0.03), GILD: 106.96 (-1.05), OGXI: 2.10 (-0.05), ANTH: 1.79 (-0.05), NVAX: 5.17 (-0.12)

After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 2.34 (-0.06), INCY: 71.59 (+0.53)

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.50 (+0.18), INCY: 71.59 (+0.53), ONTX: 4.84 (-0.01), BMY: 58.69 (-0.03), GSK: 45.61 (-0.35), STML: 14.01 (-0.94), SNTA: 3.29 (+0.04), KBIO: 2.09 (+0.11), BPTH: 2.93 (unch), CELGZ: 3.18 (-0.03), NVS: 92.90 (+0.13)

Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.35 (-0.06), BCR: 164.06 (-0.21), INCY: 71.59 (+0.53), MYL: 53.79 (+0.28), AEGR: 21.23 (-0.33)

Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.01 (+0.54), CYTX: 0.37 (-0.02), ACHN: 13.30 (+0.82), INCY: 71.59 (+0.53), SRPT: 15.14 (-0.46)

30.9% Return Seen to Date on SmarTrend Incyte Call (INCY)
Comtex SmarTrend(R) - Mon Nov 03, 9:21AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 weeks, Incyte has returned 30.87% as of today's recent price of $66.85.
INCY: 71.59 (+0.53)

Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 322.39 (-2.20), INCY: 71.59 (+0.53), LLY: 67.74 (-0.11), NVS: 92.90 (+0.13)

Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 106.90 (-0.39), BIIB: 322.39 (-2.20), INCY: 71.59 (+0.53), ILMN: 187.97 (-0.07)

Upgrade Alert for Incyte (INCY)
Comtex SmarTrend(R) - Fri Oct 31, 6:57AM CDT
Incyte (NASDAQ:INCY) was upgraded from Sell to Neutral at Goldman Sachs today. The stock closed yesterday at $64.18 on volume of 2.5 million shares, above average daily volume of 1.1 million. Potential upside of 22.5% exists for Incyte, based on a current level of $64.18 and analysts' average consensus price target of $78.64. Incyte shares have support at the 200-day moving average (MA) of $53.86 and additional support at the 50-day MA of $50.86.
INCY: 71.59 (+0.53)

Incyte ups Jakafi sales guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:13PM CDT

INCY: 71.59 (+0.53)

Incyte's (INCY) CEO Hervé Hoppenot on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:40PM CDT

INCY: 71.59 (+0.53)

Incyte (INCY) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 7:25AM CDT

INCY: 71.59 (+0.53)

Incyte beats by $0.33, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:18AM CDT

INCY: 71.59 (+0.53)

Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Business Wire - Thu Oct 30, 6:01AM CDT
--2014 guidance for Jakafi net product revenues increased to range of $350 million to $360 million, driven by continued strong growth in underlying demand
INCY: 71.59 (+0.53), NVS: 92.90 (+0.13)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:30PM CDT

FIS: 58.74 (+0.25), HST: 22.72 (-0.04), CRR: 51.00 (+0.59), CAH: 80.17 (+0.57), AMT: 99.56 (+0.06), ACIW: 18.51 (+0.10), GTI: 4.29 (-0.03), IDA: 61.99 (-0.92), CRCM: 9.18 (+0.69), CVRR: 23.22 (+0.46), BGCP: 8.58 (-0.04), GOV: 23.01 (-0.10), DFT: 31.36 (-0.04), APO: 22.95 (-0.57), FIG: 7.35 (+0.02), AMAG: 35.22 (+0.34), HAR: 108.00 (+0.67), AVP: 10.49 (+0.03), EXLS: 28.81 (+0.03), INGR: 80.31 (+0.01), ALU: 3.15 (-0.04), INCY: 71.59 (+0.53), COP: 71.52 (-0.23), GEL: 48.56 (-0.08), COR: 37.77 (-0.04), GTLS: 45.93 (+0.13), BWA: 55.33 (-0.17), CARB: 11.37 (+0.31), GLOP: 25.26 (-0.27), IDCC: 50.29 (+0.07), HEES: 38.10 (+0.11), BCO: 21.44 (+0.05), DST: 98.86 (+0.15), EPD: 37.70 (-0.03), ABMD: 33.35 (+0.26), CEVA: 15.70 (-0.09), BLL: 65.37 (-0.52), GBX: 62.43 (+0.93), GNC: 43.70 (+0.62), CVI: 48.17 (+0.37), ACOR: 34.95 (-0.96), I: 17.81 (-0.14), FCN: 40.95 (+0.13), CRNT: 1.12 (+0.02), DHX: 11.06 (+0.14), BG: 88.69 (-0.35), CME: 85.96 (-0.33), FCH: 10.79 (unch), ALLE: 52.39 (-0.13), AUDC: 4.77 (+0.04), APD: 134.73 (-0.19), DBD: 35.89 (-0.13), HGG: 5.64 (-0.04), CBM: 23.44 (-0.07), CNSL: 26.71 (+0.29), ATK: 111.64 (+0.18), ANR: 2.57 (-0.02), CI: 102.19 (+0.06), ABC: 88.40 (+0.47), GG: 19.27 (-0.32)

Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 71.59 (+0.53), TEVA: 58.38 (+0.19), AMAG: 35.22 (+0.34), ABBV: 63.90 (+0.05)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 161

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 127

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 118

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 147

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 89

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 142

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 222

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 154

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Insights: S&P 500 Forecasted Decline and Job Growth Impact

Updated Category News Views 107

Market Insights on Economic Factors Impacting S&P 500 Recent reports have revealed that the job market in the United States is displaying significant strength. According to recent statistics, there was an addition of 256,000 jobs, which paints a picture of a robust economy. However, this strong job growth can bring mixed signals for investors regarding the stock market,...

Continue Reading
Safety Tech in Fleets: Drivers Embrace Its Role

Updated Category News Views 65

Drivers Warming Up to Fleet Safety Tech Seems like most fleet drivers these days are eyeing safety tech through a fresher lens. Gone are the days when grumbling about privacy was the anthem of the disgruntled. The latest Linxup survey claims a whopping 77% of commercial fleet pros have hopped onto the safety train, happily trading privacy qualms for the perks of solid...

Continue Reading
Celebrating 50 Years of Excellence at Amerijet Airlines

Updated Category News Views 200

Amerijet International Airlines: A Milestone Celebration Amerijet International Airlines proudly celebrates its 50th anniversary this year, marking five decades of dedication to air cargo services that connect diverse regions. Founded by David Bassett in 1974, the airline began its journey as a small Part 135 air-taxi operator, operating a single leased aircraft. Over the...

Continue Reading
Petit Pot Wins $100K Prize at 2024 Real California Milk Event

Updated Category News Views 195

Petit Pot Celebrates a Momentous Achievement in Dairy Innovation In an exciting showcase of dairy innovation, Petit Pot has emerged as the grand prize winner of the 2024 Real California Milk (RCM) Excelerator competition. This prestigious award highlights the company's commitment to producing high-quality dairy-based desserts and its remarkable sales achievements in a...

Continue Reading
Exploring the Affordability and Safety Debate in Autos

Updated Category News Views 295

Affordability Angst, and a Scapegoat Nobody Asked For Echoes of old policy fights come roaring back here—every time car prices spike, somebody points at safety rules like they’re the boogeyman under the bed (and, yeah, it kinda ticks me off). Lawmakers have been poking at features like Auto Emergency Braking, and the broader affordability debate has gotten tangled up...

Continue Reading